20. Adrenoleukodystrophy
49 clinical trials,   86 drugs   (DrugBank: 29 drugs),   18 drug target genes,   112 drug target pathways

Searched query = "Adrenoleukodystrophy", "Adrenomyeloneuropathy", "AMN"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03196765
(ClinicalTrials.gov)
August 20185/5/2017Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With AdrenoleukodystrophyPhase I/II, Open-Label, Dose Escalation Study of the Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Childhood Cerebral Adrenoleukodystrophy (CCALD)X-Linked AdrenoleukodystrophyDrug: Sobetirome (NV1205)NeuroVia, Inc.NULLWithdrawn4 Years18 YearsMale0Phase 1;Phase 2Argentina;Australia;Chile;Colombia;France;Russian Federation;Ukraine;United Kingdom
2NCT01787578
(ClinicalTrials.gov)
April 20136/2/2013Safety and Pharmacodynamic Study of Sobetirome in X-Linked Adrenoleukodystrophy (X-ALD)A Prospective Safety, Tolerance, Pharmacodynamics and Pharmacokinetics Study of Sobetirome in Male Subjects Diagnosed With X-linked Adrenoleukodystrophy (X-ALD)X-Linked Adrenoleukodystrophy;AdrenomyeloneuropathyDrug: SobetiromeThomas S. ScanlanNULLWithdrawn18 Years64 YearsMale0Phase 1United States